KLKathryn A. Larkin

Kathryn A. Larkin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kathryn A. Larkin has a total of 95 co-authors. Here are the top co-authors by number of shared publications:

  • Alexandra Naba

    Department of Physiology and Biophysics, University of Illinois Chicago, Chicago, USA

    2 shared publications
  • Angelo Gaitas

    Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA

    2 shared publications
  • Arnold Han

    Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA; Columbia Center for Translational Immunology, Department of Medicine, Division of Digestive and Liver Diseases, Department of Microbiology and Immunology, Columbia University Medical Center, New York, NY 10032, USA

    2 shared publications
  • Benjamin L. Martin

    Department of Biochemistry and Cell Biology, Stony Brook University, Stony Brook, New York, USA

    2 shared publications
  • Bin Chen

    Department of Molecular, Cell, and Developmental Biology, University of California, Santa Cruz, CA, USA

    2 shared publications
  • Calvin J. Kuo

    Division of Hematology, Department of Medicine, Stanford University School of Medicine, Stanford, USA

    2 shared publications

Latest Publications

  • Open Access

    A proliferative to invasive switch is mediated by srGAP1 downregulation through the activation of TGF-β2 signaling

    by Chandrani Mondal, Majo J. Gacha-Garay, Kathryn A. Larkin, Rebecca C. Adikes, Julie S. Di Martino, Chen-Chi Chien, Madison Fraser, Ireti Eni-Aganga, Esperanza Agullo-Pascual, Katarzyna Cialowicz, et al.


  • Open Access

    A Proliferative to Invasive Switch is Mediated by srGAP1 Downregulation Through the Activation of TGFβ2 Signaling

    by Chandrani Mondal, Maria J. Gacha-Garay, Kathryn Larkin, Rebecca Adikes, Julie Di Martino, Chen-Chi Chien, Madison Fraser, Ireti Eni-Aganga, Esperanza Agullo-Pascual, Umut Ozbek, et al.

    Many breast cancer (BC) patients suffer from complications of metastatic disease. In order to extravasate efficiently and form metastasis, cancer cells have to become migratory and coordinate both invasive and proliferative programs at distant organs. Here, we identify srGAP1 as a regulator of the proliferative-to-invasive switch in BC cells. Highresolution adaptive optics/light sheet microscopy demonstrates that BC cells form actinrich protrusions to contact and cross the endothelial layer during extravasation. srGAP1 low cells display a highly motile and invasive phenotype that facilitates their extravasation from blood vessels, as shown in zebrafish and mouse models, while attenuating tumor growth. Interestingly, a population of srGAP1low cells remain as solitary disseminated tumor cells (DTCs) in the lungs of mice bearing BC tumors. Furthermore, multiphoton imaging with BC cells expressing a Cdk2 biosensor show that srGAP1 low cells enter into a G0/G1 state and remain as single cells or small clusters in the lungs. Finally, RNAseq and secretome analyses reveal that srGAP1low cells have increased Smad2 activation and TGFβ2 secretion, resulting in an increase in both invasion and p27 levels to sustain quiescence. These findings describe a novel mechanism mediating the shift from a proliferative to an invasive phenotype in BC cells in vivo and identify srGAP1 as a mediator of this phenotypic switch through a TGFβ2 signaling axis.

  • Intestinal Enteroendocrine Lineage Cells Possess Homeostatic and Injury-Inducible Stem Cell Activity

    by Kelley S. Yan, Olivier Gevaert, Grace X.Y. Zheng, Benedict Anchang, Christopher S. Probert, Kathryn A. Larkin, Paige S. Davies, Zhuan-Fen Cheng, John S. Kaddis, Arnold Han, et al.


  • Top Cited Papers
    Open Access

    Non-equivalence of Wnt and R-spondin ligands during Lgr5+ intestinal stem-cell self-renewal

    by Kelley S. Yan, Claudia Y. Janda, Junlei Chang, Grace X. Y. Zheng, Kathryn A. Larkin, Vincent C. Luca, Luis A. Chia, Amanda T. Mah, Arnold Han, Jessica M. Terry, et al.

    R-spondin and Wnt ligand families act non-redundantly and cooperatively within the same molecular pathway in the intestinal stem-cell niche to maintain stem-cell competency and drive stem-cell expansion. Wnt ligands interact with FZD and Lrp5/6-type receptors to influence diverse developmental, homeostatic and pathologic processes through β-catenin-dependent signalling. However, the promiscuity of Wnt ligands towards several receptors and the fact that Wnts can be hydrophobic make it difficult to produce therapeutic recombinant Wnts. Calvin Kuo and colleagues use a novel water-soluble Wnt agonist, developed by Chris Garcia and his team, in the mouse intestinal stem-cell niche to dissect the respective roles of R-spondin and Wnt ligands, both of which activate similar signalling receptors and pathways. They find that Lgr5+ intestinal stem cells normally differentiate unless both R-spondin and Wnt ligands are present. However, on their own, each ligand acts non-redundantly and in cooperation with Wnt agonist activating R-spondin receptors to maintain stem-cell competency.These receptorsare in turn activated in the presence of R-spondin to drive stem-cell expansion. Elsewhere in this issue, Chris Garcia and colleagues present their surrogate water-soluble Wnt agonists that have specificity towards certain FZDs.The new agonists act similarly to Wnt3 in differentiation assays towards the osteogenic lineage in vitro, can maintain intestinal organoid cultures, and have in vivo effects on the mouse liver. These water-soluble Wnt agonists could be used in a range of assays to understand this signalling pathway and modulate it in therapeutical applications. The canonical Wnt/β-catenin signalling pathway governs diverse developmental, homeostatic and pathological processes. Palmitoylated Wnt ligands engage cell-surface frizzled (FZD) receptors and LRP5 and LRP6 co-receptors, enabling β-catenin nuclear translocation and TCF/LEF-dependent gene transactivation1,2,3. Mutations in Wnt downstream signalling components have revealed diverse functions thought to be carried out by Wnt ligands themselves. However, redundancy between the 19 mammalian Wnt proteins and 10 FZD receptors1 and Wnt hydrophobicity have made it difficult to attribute these functions directly to Wnt ligands2,3. For example, individual mutations in Wnt ligands have not revealed homeostatic phenotypes in the intestinal epithelium4—an archetypal canonical, Wnt pathway-dependent, rapidly self-renewing tissue, the regeneration of which is fueled by proliferative crypt Lgr5+ intestinal stem cells (ISCs)5,6,7,8,9. R-spondin ligands (RSPO1–RSPO4) engage distinct LGR4–LGR6, RNF43 and ZNRF3 receptor classes10,11,12,13, markedly potentiate canonical Wnt/β-catenin signalling, and induce intestinal organoid growth in vitro and Lgr5+ ISCs in vivo8,14,15,16,17. However, the interchangeability, functional cooperation and relative contributions of Wnt versus RSPO ligands to in vivo canonical Wnt signalling and ISC biology remain unknown. Here we identify the functional roles of Wnt and RSPO ligands in the intestinal crypt stem-cell niche. We show that the default fate of Lgr5+ ISCs is to differentiate, unless both RSPO and Wnt ligands are present. However, gain-of-function studies using RSPO ligands and a new non-lipidated Wnt analogue reveal that these ligands have qualitatively distinct, non-interchangeable roles in ISCs. Wnt proteins are unable to induce Lgr5+ ISC self-renewal, but instead confer a basal competency by maintaining RSPO receptor expression that enables RSPO ligands to actively drive and specify the extent of stem-cell expansion. This functionally non-equivalent yet cooperative interaction between Wnt and RSPO ligands establishes a molecular precedent for regulation of mammalian stem cells by distinct priming and self-renewal factors, with broad implications for precise control of tissue regeneration.


  • Open Access

    Multiple conserved regulatory domains promote Fezf2 expression in the developing cerebral cortex

    by Matthew J Eckler, Kathryn A Larkin, William L McKenna, Sol Katzman, Chao Guo, Robin Roque, Axel Visel, John L L Rubenstein, Bin Chen

    The genetic programs required for development of the cerebral cortex are under intense investigation. However, non-coding DNA elements that control the expression of developmentally important genes remain poorly defined. Here we investigate the regulation of Fezf2, a transcription factor that is necessary for the generation of deep-layer cortical projection neurons.


  • Open Access

    Tbr1andFezf2Regulate Alternate Corticofugal Neuronal Identities during Neocortical Development

    by William L. McKenna, Jennifer Betancourt, Kathryn A. Larkin, Benjamin Abrams, Chao Guo, John L. R. Rubenstein, Bin Chen

    The molecular mechanisms regulating fate divergence of closely related, but distinct, layer 6 corticothalamic and layer 5 subcerebral projection neurons are largely unknown. We present evidence for central transcriptional mechanisms that regulate fate specification of corticothalamic (layer 6) and subcerebral (layer 5) projection neurons. We found that TBR1 promotes the identity of corticothalamic neurons and represses subcerebral fates through reducing expression ofFezf2and CTIP2. These conclusions are based on the following: (1) InTbr1−/−mice, the number of cells expressing layer 6 markers was reduced, and the number of cells expressing layer 5 markers was increased. Early-born (birthdated on E11.5) neurons ectopically expressed subcerebral neuronal markers, and extended their axons into subcerebral targets. (2) EctopicTbr1expression in layer 5 neurons prevented them from extending axons into the brainstem and the spinal cord. (3) Chromatin immunoprecipitation analysis using TBR1 antibodies showed that TBR1 bound to a conserved region in theFezf2gene. (4) Analysis ofFezf2mutants andTbr1−/−;Fezf2−/−compound mutants provided evidence thatFezf2blocks corticothalamic fate in layer 5 by reducingTbr1expression in subcerebral neurons. All neocortical regions appear to use this core transcriptional program to specify corticothalamic (layer 6) and subcerebral (layer 5) projection neurons.